Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration. Sep. 05, 2024 4:05 PM ET Amneal Pharmaceuticals, Inc. (AMRX) ...

The Food and Drug Administration (FDA) has approved Boruzu (bortezomib injection), a new presentation of Velcade (bortezomib), for ready-to-use subcutaneous (under the skin) or intravenous (IV) ...

The common practice is to use Velcade with more subcutaneous administration. That adds to that ease of administration with less risk of neuropathy for those patients. Transcript edited for clarity.

Subcutaneous delivery has been used for some time, including for well-known therapies such as trastuzumab (Herceptin), which is used in HER2-positive breast cancer, and bortezomib (Velcade), and ...

An evaluation of efficiency, safety, tolerability, patient satisfaction, and preference of subcutaneous (SQ) versus intravenous (IV) bortezomib (BTZ) administration in patients with multiple myeloma ...

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the most recent TreatmentTrends ®: Multiple ...

Sarclisa, combined with Velcade, Revlimid, and dexamethasone, was approved for newly diagnosed multiple myeloma patients ineligible for ASCT, reducing disease progression risk by 40%. Retevmo was ...

Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited announced U.S. Food and Drug Administration approval of BORUZU™, a new presentation of bortezomib for ready-to-use subcutaneous ...